BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging...
BC Innovations | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BC Week In Review | May 4, 2018
Financial News

Unity prices $85M IPO

Unity Biotechnology Inc. (NASDAQ:UBX) raised $85 million late May 2 through the sale of 5 million shares at $17 in an IPO underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. The price was at...
BC Extra | May 2, 2018
Financial News

Unity prices $85M IPO

Unity Biotechnology Inc. (NASDAQ:UBX) raised $85 million late Wednesday through the sale of 5 million shares at $17 in an IPO underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. The price was at the...
BC Week In Review | Apr 13, 2018
Financial News

Unity proposes $85M IPO

On April 5, Unity Biotechnology Inc. (Brisbane, Calif.) filed to raise up to $85 million in an IPO on NASDAQ underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. Unity's lead candidates target senescent cells...
BC Extra | Apr 6, 2018
Financial News

Age-related disease play Unity planning IPO

Unity Biotechnology Inc. (Brisbane, Calif.) filed to raise up to $85 million in an IPO on NASDAQ underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. Unity's lead candidates target senescent cells to treat age-related...
BC Week In Review | Mar 23, 2018
Financial News

Unity raises $55M series C

Unity Biotechnology Inc. (San Francisco, Calif.) raised $55 million in a series C round on March 19. New investors EcoR1 Capital Fund, 6 Dimensions Capital and Altitude Life Sciences Ventures participated, as did existing investors...
BC Extra | Mar 19, 2018
Financial News

Unity raises $55M series C

Unity Biotechnology Inc. (San Francisco, Calif.) raised $55 million in a series C round. New investors EcoR1 Capital Fund, 6 Dimensions Capital and Altitude Life Sciences Ventures participated, as did existing investors Fidelity, Baillie Gifford,...
BC Innovations | May 3, 2017
Distillery Therapeutics

Autoimmune disease

INDICATION: Osteoarthritis Patient sample and mouse studies suggest promoting senescent cell clearance could help treat osteoarthritis (OA). In patient-derived cultured human cartilage, a compound that induces apoptosis in senescent cells ( UBX0101 ) increased proliferation of healthy...
Items per page:
1 - 9 of 9